Beta-adrenergic blockade may prolong life in post-infarction patients in part by increasing vagal cardiac inhibition.
Beta-adrenergic blocking drugs prolong lives of post-infarction patients primarily by preventing sudden cardiac death. The mechanisms responsible for this beneficial effect are not understood clearly, since beta-blockers, in doses used in most clinical trials, are only weakly effective against stable ventricular arrhythmias. Arrhythmias during myocardial ischemia may differ from arrhythmias in other clinical settings in that they depend importantly upon autonomic neural factors, including the balance between levels of sympathetic cardiac stimulation and parasympathetic cardiac inhibition. Beta-blockers reduce sympathetic cardiac stimulation, and they may influence this balance favorably in another important way: a well documented, but not generally appreciated property of beta-blocking drugs is that they also increase levels of vagal cardiac inhibition. I propose that beta-blockade prevents arrhythmic deaths in post-infarction patients in part by increasing levels of vagal cardiac inhibition.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D003645:Death, Sudden; D004285:Dogs; D006321:Heart / Q000294:innervation; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D009433:Neural Inhibition / Q000187:drug effects*; D013997:Time Factors; D014630:Vagus Nerve / Q000187:drug effects* / Q000502:physiology
D000319:Adrenergic beta-Antagonists